Patents Assigned to CureTech Ltd.
-
Patent number: 9580504Abstract: Methods for treating specific populations of cancer patients, specifically patients suffering from cancer who undergo stem cell transplantation and were classified as positive by a pre-transplant metabolic imaging, by administering to the subject a therapeutically effective amount of a pidilizumab monoclonal antibody.Type: GrantFiled: November 7, 2014Date of Patent: February 28, 2017Assignee: CureTech Ltd.Inventors: Rinat Rotem-Yehudar, Michael Schickler
-
Patent number: 9416175Abstract: The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1.Type: GrantFiled: March 18, 2014Date of Patent: August 16, 2016Assignee: CureTech Ltd.Inventors: Rinat Rotem-Yehudar, Michael Schickler
-
Patent number: 9309308Abstract: A method of treating a tumor or enhancing survival of a subject having a tumor. The method includes (i) administering to a subject in need thereof an effective amount of a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has all complementarity determining regions of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; and (ii) administering to the subject an effective amount of at least one chemotherapeutic agent selected from the group consisting of: 5-fluorouracil, cytarabine, oxaliplatin, paclitaxel and combinations thereof. The humanized antibody is administered between 1 and 30 days after commencing chemotherapy or substantially simultaneously or concurrently or according to an overlapping schedule with the at least one chemotherapeutic agent to thereby treat the tumor or enhance the survival of the subject having the tumor.Type: GrantFiled: April 29, 2014Date of Patent: April 12, 2016Assignee: CureTech Ltd.Inventors: Rinat Rotem-Yehudar, Galina Rodionov
-
Publication number: 20140302032Abstract: A method of treating a tumor or enhancing survival of a subject having a tumor. The method includes (i) administering to a subject in need thereof an effective amount of a humanized monoclonal antibody or a fragment thereof, wherein the antibody or the fragment thereof has all complementarity determining regions of murine monoclonal antibody BAT (mBAT-1) and a framework region (FR) from an acceptor human immunoglobulin, or modified therefrom; and (ii) administering to the subject an effective amount of at least one chemotherapeutic agent selected from the group consisting of: 5-fluorouracil, cytarabine, oxaliplatin, paclitaxel and combinations thereof. The humanized antibody is administered between 1 and 30 days after commencing chemotherapy or substantially simultaneously or concurrently or according to an overlapping schedule with the at least one chemotherapeutic agent to thereby treat the tumor or enhance the survival of the subject having the tumor.Type: ApplicationFiled: April 29, 2014Publication date: October 9, 2014Applicant: CURETECH LTD.Inventors: Rinat ROTEM-YEHUDAR, Galina RODIONOV
-
Publication number: 20140220010Abstract: The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1.Type: ApplicationFiled: March 18, 2014Publication date: August 7, 2014Applicant: CURETECH LTD.Inventors: Rinat ROTEM-YEHUDAR, Michael SCHICKLER
-
Patent number: 8747847Abstract: The present invention relates to methods for inhibiting tumor growth, increasing survival of a subject having a tumor and inducing protection against tumor recurrence in a mammal. The methods comprise administering a humanized monoclonal antibody comprising CDR regions derived from the murine monoclonal antibody designated mBAT-1, in combination with at least one chemotherapeutic agent.Type: GrantFiled: February 11, 2009Date of Patent: June 10, 2014Assignee: CureTech Ltd.Inventors: Rinat Rotem-Yehudar, Galina Rodionov
-
Patent number: 8686119Abstract: The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1.Type: GrantFiled: July 23, 2012Date of Patent: April 1, 2014Assignee: CureTech Ltd.Inventors: Rinat Rotem-Yehudar, Michael Schickler
-
Publication number: 20130022595Abstract: The present invention relates to humanized monoclonal antibodies, pharmaceutical compositions that include the same, and use thereof for the treatment of a variety of indications, particularly cancer and immunodeficiency disorders. In particular, the present invention provides modified antibodies or fragments thereof having specific amino acid modifications compared to the humanized monoclonal immunomodulatory antibody termed hBAT-1.Type: ApplicationFiled: July 23, 2012Publication date: January 24, 2013Applicant: CURETECH LTD.Inventors: Rinat Rotem-Yehudar, Michael Schickler
-
Patent number: 7981416Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.Type: GrantFiled: March 18, 2009Date of Patent: July 19, 2011Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
-
Patent number: 7745397Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.Type: GrantFiled: December 14, 2007Date of Patent: June 29, 2010Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Annat Raiter, Leah Klapper
-
Patent number: 7524498Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.Type: GrantFiled: September 12, 2007Date of Patent: April 28, 2009Assignees: CureTech Ltd., Mor-Research Application Ltd.Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
-
Publication number: 20080175855Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.Type: ApplicationFiled: December 14, 2007Publication date: July 24, 2008Applicants: Curetech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Annat Raiter, Leah Klapper
-
Patent number: 7332582Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.Type: GrantFiled: November 19, 2004Date of Patent: February 19, 2008Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
-
Patent number: 7329639Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.Type: GrantFiled: April 27, 2006Date of Patent: February 12, 2008Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Annat Raiter, Leah Klapper
-
Publication number: 20080025980Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.Type: ApplicationFiled: September 12, 2007Publication date: January 31, 2008Applicants: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Steven Jones, Leah Klapper
-
Patent number: 7122372Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.Type: GrantFiled: April 9, 2004Date of Patent: October 17, 2006Assignees: CureTech Ltd., Mor-Research Applications Ltd.Inventors: Britta Hardy, Annat Raiter, Leah Klapper
-
Publication number: 20060210573Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.Type: ApplicationFiled: April 27, 2006Publication date: September 21, 2006Applicants: Curetech Ltd.,, Mor-Research Applications Ltd.,Inventors: Britta Hardy, Annat Raiter, Leah Klapper